Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
FDA Grants HDE Approval to OncoSil for Distal Cholangiocarcinoma
FDA Lists More Than 1,500 AI-Enabled Medical Devices as Oncology Applications Expand
Simplify Your ESO College Enrolment With Our New 3-Year Plan - ESO
oncoHUB and OncoDaily Announce Strategic Partnership to Strengthen Ukrainian Oncology
Bridging the Care Gap: Expanding Humanitarian Access to CLL Treatment Across LMICs
ENZAMET: Enzalutamide Maintains Long-Term Survival Benefit in mHSPC
Human Connection in Cancer Care with Dr. Aleksandra Filipovic - CancerWorld
